Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

BACKGROUND: Patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) receiving platinum-based chemotherapy as their first-line treatment have a dismal prognosis, with a median overall survival (OS) of ~7 months. Methotrexate is sometimes used following platinum f...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Machiels, Jean-Pascal H, Licitra, Lisa F, Haddad, Robert I, Tahara, Makoto, Cohen, Ezra EW
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2014
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4079914/
https://ncbi.nlm.nih.gov/pubmed/24973959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-14-473
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados